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1. Introduction 
Despite widespread use of evidence-based therapies the morbidity and mortality of heart 
failure has not changed, and it remains the most common hospital discharge diagnosis for 
patients older than 65 years old of age. Approximately 5 million patients in the United States 
of America have cardiac failure, and over 550,000 patients are diagnosed with heart failure 
for the first time each year (Levy et al, 2002; Hunt et al, 2005).  The European Society of 
Cardiology represents countries with a population of more than 900 million, and in their last 
guidelines they reported that there are at least 15 million patients suffering this disease in 
those 51 countries (Dickstein et al, 2008). Heart failure is primarily a condition of the elderly 
(Kannel & Belanger, 1991), and thus the widely recognized “aging of the population” also 
contributes to the increasing incidence of heart disease. The incidence of cardiac failure 
approaches 10 per 1,000 population after age 65 years, and approximately about 80% of 
patients hospitalized with heart failure are older than 65 years old (Masoudi & Havranek, 
2002).  
There are several reasons that may explain why the prevalence of heart failure is increasing: 
ageing of the population, the success in prolonging survival in coronary patients, and the 
success in postponing coronary events by effective prevention in those patients at high risk 
or those patients who have already survived a first event (secondary prevention) (Senni et 
al, 1999). Advances in medical therapy have resulted in improved survival in patients with 
moderate and severe heart failure, but the prognosis for end-stage heart failure patients still 
remains poor. The conclusion of all these aspects is that there is a change in the 
demographics of heart failure patients in recent years, and an increased survival of older 
patients with heart disease.  
At present time, cardiac transplantation remains the gold standard of cardiac replacement 
therapy. However, the supply of donor hearts is limited and therefore is not an option for 
many patients because of age and other comorbid conditions. Alternative forms of  
cardiac replacement therapy are being investigating. This includes cell therapy, 
xenotransplantation, ventricle assist devices implantation and total artificial heart. 
Although initially the indications for heart mechanical assistance are similar to those 
developed in the1960s for the use of intra-aortic balloon pumps the indications have 
developed into more complex cases which must be considered. Ventricle assist devices are 
more and more reliable and its size is becoming smaller with the passing of time, improving 
patient’s outcomes. 
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2. Cardiac transplantation: where we are and what can we expect 
The first human cardiac transplant was performed by Dr. Barnard in Cape Town in South 
Africa in 1967. With the development of immunosuppression, orthotopic cardiac 
transplantation, what exists today, is a highly successful procedure for the treatment of end-
stage heart disease. Over time, survival of patients undergoing orthotopic heart 
transplantation has improved significantly, mainly due to a reduction in rejection rates, 
better prevention and treatment of opportunistic infections and defined management 
protocols (Taylor D et al, 2008). 
Indications for cardiac transplantation at the present time include patients with severe heart 
failure symptoms, a poor prognosis, and with no alternative form of treatment (class of 
recommendation I, level of evidence C). Contraindications to heart transplantation are: 
current alcohol and/or drug abuse, lack of proper cooperation, serious mental disease not 
properly controlled, treated cancer with remission and, 5 years follow-up, systemic disease 
with multiorgan involvement, active infection, significant renal failure (creatinine clearance 
<50 mL/min), irreversible high pulmonary vascular resistance (6–8 Wood units and mean 
transpulmonary gradient >15 mmHg), recent thromboembolic complications, unhealed 
peptic ulcer, evidence of significant liver impairment, or other serious co-morbidities with a 
poor prognosis. Patients must be well informed, motivated, emotionally stable, and capable 
of complying with intensive medical treatment.  
According to the registry of the International Society for Heart and Lung Transplantation 
reported in 2008 (Taylor D et al, 2008) the one-year survival after primary orthotopic cardiac 
transplantations has increased from 79% between 1982 and 1991, to 82% between 1992 and 
2001, and to 86% between 2002 and 2005 (p<0.0001). However, long-term mortality has not 
changed and in fact the overall survival patterns remain largely unchanged with a steep fall 
in survival up to 6 months and linear decrement in survival thereafter, at approximately 
3.5% per year (figure 1) 
Some factors need to be in consideration, as they are changing the demographics of heart 
transplantation. The primary cardiac transplantation has shifted in the last years towards a 
 
 
Fig. 1. Kaplan-Meier survival for all cardiac transplants (1/1982-6/2006) (Taylor D et al, 
2008) 
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slight predominance of patients with nonischemic cardiomyopathy (50%) vs. ischemic 
(34%). It is a fact that the relative contribution of patients with ischemic cardiomyopathy has 
declined over the last decade. Also the age of donors and recipients has increased in the past 
20 years. Almost 25% of cardiac transplant patient recipients in the last years were over the 
age of 60 years, with a relative fall in the number of recipients aged 40-49 years. Also at the 
present time the number of transplants being performed worldwide is far outnumbered by 
the number of potential candidates, as donor hearts are a very limited resource. These 
aspects are essential in the understanding of patient outcomes and they explain why other 
alternatives to heart transplantation should be investigated in an effort to offer alternative 
therapies to those patients suffering severe heart failure.  
The need for those alternative therapies include the lack of cardiac donors, long cardiac 
transplantation waiting list, patients with any contraindication to cardiac transplantation 
(definitive or temporal) and patients requiring more time for the heart to recover.  
The use of ventricle assist devices has acquired an important role in the management of end-
stage heart failure and it is very likely that its importance will increase with time. 
Historically, the development of cardiopulmonary bypass technology in the fifties was the 
achievement that really started the development of more permanent means of mechanical 
cardiac support. Technological progress has allowed the design and production of smaller 
devices that have bridged patients towards recovery and transplantation. 
In this chapter we will review the indications of ventricle assist devices implantation. We 
will star giving some general indications that every patient should follow from a theoretical 
point of view. Then we will divide the indications in three different groups: 1) bridge to 
transplantation, 2) bridge to recovery and 3) destination therapy.  
We will also discuss when it is required to use a short term ventricle assist device, a long 
ventricle assist devices and the total artificial heart. Finally we will review in the literature 
when it is necessary to have a right ventricle assist device especially when a left ventricle 
assist device is already implanted. 
The authors would like to remark that this chapter is a compilation of the literature 
regarding ventricle assist device therapy. Therefore each patient must be considered as a 
particular case and there are no strict rules or guidelines to be followed. 
3. General indications for ventricle assist device implantation 
The general rule is simple: ventricle assist devices are used when the heart is incapable of 
maintaining its function. Therefore, the organism is in danger or is going to be in danger 
because cardiac output is not enough to maintain vital organ flow. Cardiac dysfunction may 
be caused in an acute fashion, like in a cardiogenic shock caused by an extensive myocardiac 
infarction or after a major cardiac surgery when a patient is not able to weaned from the 
heart-lung machine. Also, cardiac failure may be a consequence of a chronic condition like 
in the ischemic chronic heart disease or in patients with dilatated myocardiopathy.  
There are some registries that compile from different centers the indications for a ventricle 
assist devices implantation. These registries are a good resource of information about what 
the indications of ventricle assist device are. One of the databases is the Interagency Registry 
for Mechanical Assisted Circulatory Support (INTERMACS), which is an audited registry 
for patients who receive a mechanical circulatory support device to treat advanced 
medically refractory heart failure. From June 2006 to December 2007, a total of 75 
institutions in the United States of America prospectively entered 420 patients. Most of the 
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patients (n=336) had a mechanical circulatory support device implanted for the indication of 
bridge to transplantation. The indication of destination therapy was applied in 63 patients 
whereas the rest of patients received a ventricle assist device as a bridge to recovery 
(Holman et al, 2009). This perfectly describes what the indications in the clinical practice are 
at the present time. Several aspects must be considered for indicating a ventricle assist 
device: 
3.1 Clinical status 
Patients requiring a ventricle assist device suffer severe heart failure acutely or chronically. 
When cardiac failure has been caused acutely, the patient is in cardiogenic shock. This may 
be from different causes: extensive acute myocardial infarction (Killip IV), mechanical 
complications after an infarction (papillary muscle rupture, interventricular septal rupture), 
patients that cannot be weaned from the cardiopulmonary bypass machine, acute 
myocarditis and others. It should be noticed that the use of ventricle assist device in the 
setting of cardiogenic shock must be contemplated when the use of inotropes and intra-
aortic ballon pump is not enough to maintain an adequate cardiac output and there is a risk 
of death or other organ failure. Also, there should be no other options such as major cardiac 
surgery or other surgical options that may reverse the status of the patient.  
However, although ventricle assist devices are not the first treatment option in this type of 
situation, their implantation should not be delayed. Most cardiologist and cardiac surgeons 
agree to implant a ventricle assist device in patients with severe heart failure, despite intra-
aortic balloon pump or inotropic support with unstable hemodynamics, and with early 
signs of end-organ dysfunction (Osaki et al, 2009). In the last years, there has been an 
attempt to prevent deterioration of the ventricle assist device candidate’s condition. 
Actually, whenever possible some co-morbid conditions should be nullified by a period of 
therapy prior to implant. Some examples are renal dysfunction, localized infection or severe 
pulmonary edema, which can be reversed with medical therapy prior to a mechanical 
device implantation. Every patient should be in the best clinical position, considering that 
these patients are in a really bad clinical status, avoiding the implantation in pre-mortem 
conditions. This rule should also be applied in those patients with end-stage chronic cardiac 
dysfunction. Mechanical device implantation should be kept in mind before other organs 
deteriorate. This will definitely improve clinical outcomes. Other clinical conditions that 
may indicate the use of some mechanical support are intractable arrhythmias and intractable 
angina not responsive to medical therapy or revascularization procedures in patients with 
poor left ventricle function. 
3.2 Hemodynamic parameters 
A hemodynamic study may be required in some situations to assure that cardiac function is 
severely deteriorated. Table 1 summarizes hemodynamic data that represent severe left and 
right ventricle dysfunction. 
4. Ventricle assist device as bridge to transplantation 
As we have previously descibed in the introduction section, orthotopic cardiac transplantation 
is the gold standard for treating end-stage heart failure. The International Society for Heart 
and Lung Transplantation (ISHLT) has reported outcome data on transplant recipients for 
more than 25 years with data that includes more than 74,000 patients (Taylor et al, 2008). 
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Left ventricle assist device Right ventricle assist device Biventricular ventricle 
assist device 
Systolic blood pressure 
<90mmHg 
Right atria pressure > 
20mmHg 
Right atria pressure > 
20mmHg 
Left atria pressure > 
20mmHg 
Left atria pressure < 
15mmHg 
Left atria pressure > 
20mmHg 
Systemic vascular 
resistance >2,100 dynes-
sec/cm 
No tricuspid regurgitation No tricuspid regurgitation 
Urine output <20mL/h  Inability to maintain left 
ventricle assist device flow 
>2.0L/min/m2 with right 
atrial pressure >20mmHg 
Table 1. Haemodynamic indications for circulatory assist device 
This registry includes data mainly from USA and European countries. We see from those 
reports that primary indications for cardiac transplantation has changed with an increase of 
patients with nonischemic cardiomyopathy and less ischemic patients. In addition, the age 
of donors and recipients has been increasing in the last 20 years, especially in Europe. It is 
clear that heart donors are a limited resource and some patients die while awaiting cardiac 
transplantation due to that lack of donors. Actually, in the last two decades, decreasing 
numbers of organ donors have led to longer waiting times for cardiac transplantation and 
subsequently increasing mortality. Other patients´ statuses may worsen while waiting and 
they may need some kind of cardiac circulatory support in order to maintain vital blood 
flow and preserve organ systems like kidney, hepatic, or brain function. 
Therefore, we can summarize that ventricle assist device as a bridge to transplantation is 
indicated in those patients that are candidates for cardiac transplantation and need some 
cardiac support while they are waiting for the heart. This indication includes a wide 
spectrum of patients. On one side, we may have patients that suffer an acute event 
(postinfarction cardiogenic shock, postcardiotomy) which leads them into an irreversible 
severe heart failure that requires urgent cardiac transplantation. Until a donor is found, 
cardiac mechanical support is necessary to save patients life and to preserve their vital 
organs. As we will see later, organ failure is associated with a worse prognosis after heart 
transplantation. On the other side, there are patients that are awaiting cardiac 
transplantation and whose conditions become refractory to medical therapy. 
At present time, ventricle assist devices are an important tool in the management of this 
kind of patient (Frazier at al, 2001; Miller et al, 2007; Russo et al, 2009). Also, in the last 
decade, the number of heart transplant recipients supported by ventricle assist devices at the 
time of transplantation has more than doubled to over 400 per year in the USA (Taylor DO 
et al, 2008) as well as in European countries. This clearly reflects the need of mechanical 
circulatory support in patients awaiting transplantation. Also as previously described, if we 
consider some registries as the INTERMACS, bridge to transplantation is by far, the most 
frequent indication for a ventricle assist device implantation (Holman et al, 2009). 
There are some questions that should be answered regarding mechanical circulatory 
support as a bridge to transplantation. 
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1. Does the use of a ventricle assist device as a bridge to transplantation affect the outcome 
of patients when compared to those patients who receive transplants without the need 
of mechanical assistance? 
2. When should one implant a mechanical device in a patient awaiting cardiac 
transplantation? 
3. What kind of device should be implanted? 
Although several studies have demonstrated the benefits of ventricle assist devices in the 
pretransplant period, findings from studies analyzed the impact of mechanical circulatory 
support on posttransplant outcomes have conflicted. The majority of studies have concluded 
that short term, but not long term, survival is diminished in recipients bridge with a 
mechanical device (Taylor DO et al, 2008; Cleveland JC et al, 2008). However, there are some 
reports that do not confirm these findings. In a recently published study (Osaki et al, 2009)  
Osaki et al compared patients´ outcomes undergoing cardiac transplantation with and 
without the use of a ventricle assist device. They also divided patients in two different time 
groups as an attempt to analyze both, the experience of the group and the improvement of 
devices technology. A total of 531 consecutive heart transplant recipients in a 17 years 
period were included. They concluded that post-transplant survival has improved in the last 
years. Actually in their study, outcomes for orthotopic heart transplantation after bridge to 
transplantation have become equivalent to that of orthotopic heart transplantation without 
ventricle assist device. The data suggest that advances in device technology and 
multidisciplinary programs, have improved survival and allowed bridges to transplantation 
candidates to have an outcome equivalent to that of non-ventricle assist device in recent 
times (Figure 2). 
 
 
Fig. 2. Post-transplant survival by Kaplan–Meier analysis. oOHT, old orthotopic heart 
transplant (January 1990 to July 2003); nOHT, new orthotopic heart transplant (August 2003 
to August 2007); oBTT, old bridge to transplant (January 1990 to July 2003); nBTT, new 
bridge to transplant (August 2003 to August 2007). 
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In that study, multivariate analysis revealed that diabetes and biventricular (but no 
univentricular) support were the only independent predictors of post-transplant mortality. 
These findings have been confirmed by other groups (Russo et al, 2009). In the study 
published by Russo et al, they included more than 10,000 heart transplantation recipients 
from the United Network for Organ Sharing in a seven-year period. They concluded that the 
use of implantable left ventricle assist devices (both intracorporeal and extracorporeal 
devices) as bridges to transplantation are not associated with diminished posttransplant 
survival. However, an increase in 90-day mortality was seen in patients bridged with 
extracorporeal devices. 
These findings suggest that more than 80% of well-selected patients implanted with 
intracorporeal devices as a bridge to transplantation are successfully transplanted, 
providing additional evidence that a more aggressive use of implantable devices may 
benefit candidates whose condition is refractory to medical management. Outcomes seem to 
be better when implantable device support is implemented before patients clinical status 
deteriorates badly. The findings further suggest that a more aggressive use of implantable 
support may benefit candidates who are likely to face long waiting times as candidates with 
higher body mass index or blood type O. The fact that patient survival is diminished in 
patients with extracorporeal devices may suggests that in some cases, candidates supported 
by an extracorporeal device may benefit from further optimization before transplantation, 
and that this type of devices may be best used as a bridge to an implantable device 
especially in those patients that may have long waiting times.  
As it has been suggested in other studies (Cleveland et al, 2008), the general perception 
among most cardiac transplantation centres is that explantation of a ventricle assist device 
confers a more technically challenging operation and therefore, might adversely affect 
survival not in medium term but in a short term. In the Cleveland group experience, one 
year survival was similar in those recipients receiving a heart transplantation with or 
without a mechanical circulatory support. However, when they analyzed patients who died 
after transplantation, most of the ventricle assist device group died within 30 days of 
transplant. In contrast, only a minority of patients without a mechanical assist device died 
within those thirty days.  
This may reflect an inherent complexity and higher risk operation that occurs in the 
explantation of a ventricle device. 
It is essential to have a good knowledge of the heart transplantation situation in every 
country. There are some countries such as Spain, where there is a high prevalence of donors 
and where the waiting times are not to long. Short term extracorporeal devices may be used 
as they are less expensive and very simple to use. Good results can be achieved this way 
(Reyes et al, 2007). In other countries like Germany or the USA where the waiting times are 
much longer, long term assistance may be a better option (Korfer et al, 1999). 
5. Ventricle assist device as bridge to recovery 
Ventricle assist devices have been successfully implanted in patients who are expected to 
recover sufficient myocardial function and it is not expected that they will need a cardiac 
transplantation.  In this type of patient a short-term bridge to recovery device may be a good 
option as these devices are less expensive and very easy to use (Samuels et al, 2005; Nicolini 
& Gherti, 2009). The most frequent clinical settings in which a mechanical circulatory 
support may be needed are described below: 
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5.1 Post-cardiotomy 
Patients with compromised left ventricle function who have undergone long operations may 
need a ventricle assist device because the severity of the postoperative circulatory shock. It 
is estimated that about 5% of patients undergoing coronary or valve cardiac procedures will 
have some degree of postcardiotomy cardiogenic shock (Pae et al, 1992). Short term 
mechanical support as bridge to recovery has been successfully used in patients who are 
expected to recover sufficient myocardial function. Since the ABIOMED system was 
approved by the Food and Drug Administration in 1992, it has become the second most 
commonly used mechanical support device for patients with post-cardiotomy ventricular 
dysfunction after the intra-aortic balloon pump with excellent rates of myocardial recovery 
and device removal after short-term support (Morgan et al, 2004). We highly recommend 
the early implantation of mechanical circulatory assistance in this clinical setting to provide 
mechanical unloading of the ventricle and rapid restoration of normal end-organ perfusion 
in order to improve survival rates. 
In those patients in whom a high risk of cardiac failure is anticipated (severely impaired 
ventricular function undergoing high risk cardiac procedures) transplant evaluation should 
be initiated preoperatively and the procedure performed with a ventricle assist device back 
up. If needed it, mechanical support may be used as bridge to recovery or bridge to 
transplantation. 
5.2 Post acute myocardial infarction shock 
Despite the advances in the management of cardiogenic shock secondary to acute 
myocardial infarction, the prognosis is still poor with mortality rates as high as 70% 
(Goldberg RJ et al, 1999). There are some aspects that must be considered in this clinical 
setting. One of the surgical dilemmas, when implanting an LVAD into a patient with an 
acute anterior wall myocardial infarction, is the safety of apical cannulation in the presence 
of acutely infarcted apical myocardium, which is typically necrotic and friable. Ventricular 
disruption and bleeding from the cannulation site are major concerns with lethal 
consequences. Although left atrial cannulation is an option, it is suboptimal as it affords 
inadequate left ventricular decompression and limits LVAD inflow. Furthermore, left atrial 
cannulation has been shown to have independent risk factors for the development of left 
ventricular thrombus and stroke. There are some surgical techniques that should be 
considered. Some authors have maintained that left ventricle devices can be safely 
implanted into acutely infarcted, friable myocardium by modifying their surgical technique. 
This involves placing cannulation sutures through the full thickness of the infarcted 
ventricular myocardium and reinforcing their suture line with pericardium or Teflon felt 
(Park SJ et al, 2000; Chen et al, 1999). Other technique used in patients with cardiogenic 
shock and with extensive anterior wall infarcts, consists of securing the cannula with 
interrupted, pledgeted, horizontal mattress sutures through the full-thickness of the 
infarcted myocardium. If significant bleeding is observed, additional sutures and/or 
haemostatic products can be applied to the cannulation site (Leshnower et al, 2005). 
It is important to highlight that patients with ventricle assist devices due to cardiogenic 
shock after an acute myocardial infarction may follow different outcomes. In this situation 
there should be flexibility to the treatment algorithm that these patients may follow.  
Mechanical circulatory system may be used as a bridge to recovery, a bridge to bridge (to 
other long term assist device system) or as a bridge to transplant. Also, some authors 
consider that the use of a biventricular assist device is important in these patients 
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(Leshnower et al, 2005). This must be taken in consideration in right ventricular heart 
failure, intractable arrhytmias and in the presence of shock with multisystem organ failure.  
Recently, some authors consider that less invasive percutaneous ventricular assist devices 
may be helpful in the decision making of the treatment as they are less expensive and 
sternotomy is not required, which may helps subsequent transplantation or surgically 
ventricle assist device insertion (Brinkman et al, 2010).  
5.3 Myocarditis 
Myocarditis may cause severe cardiac failure, sometimes very acutely. It is believed that 
almost every infectious agent can cause myocarditis (bacterias, virus, spiroquetas, mycotic 
infections, parasital agents, ricketsias). Also there may be immunologic causes as the so call 
giant cells myocarditis in which, apart from inmunosupresor therapy, ventricle assist device 
may be needed. These patients trend to be younger (many of them children) and it is 
characterized by an unpredictable clinical course. Actually it remains a real challenge to 
determine which group of patients will recover and which will require mechanical support 
or heart transplantation (Houel R et al, 1999). As myocarditis is an inflammatory process 
that affects the whole myocardium (both the right and left ventricle) it is frequent that 
biventricular support is required (Grinda JM et al, 2004). As we have previously said it is 
important anticipate the prognosis of the patient in order to convert a short-term assist 
device into a long term assist device or cardiac transplantation in those patients in which an 
optimal recovery is not expected. 
6. Destination therapy 
Ventricle assist device as a destination therapy has some aspects that may concern 
cardiologists and cardiac surgeons. It is necessary to know how the mechanical devices may 
affect survival rates compared with alternative treatment strategies, the durability of the 
devices, and its safety profile. Also we must take into account the quality of life of these 
patients and if the up-front costs of implantation may be offset by the long-term benefits of 
the patients. 
The Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive 
Heart Failure (REMATCH) trial is a multicentered study supported by the National Heart, 
Lung, and Blood Institute. It compares long-term implantation of left ventricular assist 
devices with optimal medical management for patients with end-stage heart failure who 
require, but do not qualify to receive cardiac transplantation. This trial demonstrated that 
the implantation of left-ventricular assist devices decreased the 1-year mortality by a third 
(from 75% down to 51%) and the two year survival rate was 29% for left ventricle assist 
device patients versus 13% for medical patients (95% CL; 5%-22%), representing a 48 percent 
reduction in the risk of death from any cause, compared with the optimal medical therapy. 
The survival advantage was associated with a considerable improvement in the quality of 
life and functional status of these patients, as compared with their medical counterparts 
(Rose et al., 1999). The MLHF scores, (Minnesota Living with Heart Failure questionnaire) 
for left ventricle assist device patients were 75.1 (0 being the best – 105 the worst). The 
REMATCH trial demonstrated that is superior to any available medical therapy in patients 
with end-stage heart failure who are not eligible for transplantation (Lietz & Miller, 2005). 
The Thoratec HeartMate was subsequently approved in 2003, by the Food and Drug 
Administration (FDA), for long-term support of this kind of patient. 
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The next logical step for expanding the indications for mechanical circulatory assistance 
would be to use the left ventricle assist device as an alternative to cardiac transplantation. 
However, heart transplantation cannot serve the estimated 30,000–60,000 people who die of 
heart failure in the US each year and could be candidates for heart transplantation or some 
form of mechanical circulatory support. More than 40% of the patients waited more than 1 
year for a cardiac transplantation, and the waiting time is increasing every year. In 1995, the 
average waiting time for cardiac transplantation was over 200 days (Penningtonet al., 1999), 
but the average national waiting time in 2003 for a heart was 230 days (UNOS/OPTN 
Annual Report 2003). Each year, approximately 4000 new patients are added to the waiting 
list for cardiac transplant, and about 28,000–30,000 are apparently not considered viable 
candidates to be placed on the list. About 50%of the patients not included in the waiting list 
(13,000) would be candidates for a permanent ventricular assist device. An important 
deterrent to being listed may be advanced age. 
The most obvious advantage of these mechanical device systems over transplantation would 
be their immediate availability. They could be placed in UNOS status II rather than UNOS 
status I hospital-bound patients. Table 2 shows the indications and characteristics of the 
total artificial heart. 
 
Total artificial 
heart 
Characteristics Use Cost 
Abiomed Total 
Artificial Heart 
TAH is currently 
undergoing clinical 
trials 
CardioWest 
device 
Is inserted 
orthotopically; this 
procedure is 
accompanied by 
removal of the 
patient's own 
ventricles 
Pneumatic TAH that 
has been used 
investigationally as a 
bridge to 
transplantation 
The cost of these 
devices is likely to be 
quite high, but may 
not be very different 
from the cost of heart 
transplantation, 
therapy and 
immunosuppression. 
 
Table 2. Indications and characteristics of the total artificial heart. TAH: Total artificial heart. 
6.1 Exercise capacity 
An important determinant of quality of life in cardiac transplant recipients and left ventricle 
assist device recipients is exercise capacity. 
Studies in cardiac transplant recipients demonstrate that, at rest, they have an increased 
heart rate, increased blood pressure, and low normal cardiac output. During exercise, peak 
heart rate, stroke volume, cardiac output, peak power output, pulse pressure, heart rate 
reserve, total VO2, and absolute VO2 at ventilatory threshold are all less than normal. Their 
exercise capacity may increase with time up to 5 years and may improve with an increase in 
muscle mass and lean body weight. Autonomic reenervation may actually increase the peak 
heart rate during exercise, although this is quite controversial. Recent studies suggest that 
cavo-caval anastomosis may increase atrial emptying, resulting in better functional capacity. 
While some individual patients with cardiac transplantation function well, most patients 
have important physiological limitations. 
The exercise capacity of patients with implantable mechanical cardiac devices is based on 
the results obtained during the use like bridge to transplant, it is apparent that improvement 
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in exercise tolerance occurs. Maximum VO2 is a well-characterized indicator of functional 
status and prognosis in patients with advanced heart failure.  
Peak oxygen consumption with upright treadmill exercise increased from 10 to 14 mL 
O2/kg/min in a group of patients supported for a mean of 50 days after left ventricle assist 
device implantation. Pennington et al remarked that many postoperative studies suggest 
that the native left ventricle may contribute to this function during exercise by actively 
filling the left ventricle assist device, which reduces filling time and overcomes inflowing 
cannula impedance. It may also augment total cardiac output with parallel ejection out of 
the native aortic valve and reduce ventricular interaction-related changes in functional right 
ventricular diastolic compliance. 
It is clear that exercise capacity increases during the first several months after ventricle assist 
device insertion because patients have improved organ function, reducing pulmonary 
edema and pulmonary artery resistance. These changes significantly augment right 
ventricular function, which also usually improves with time.  
It is anticipated that patients with long-term left ventricle assist devices will achieve 
reasonably high levels of exercise capacity and they will not be limited by activities of daily 
living. Whether they will be able to participate in athletic events and vigorous work is not 
entirely clear, but seems feasible (Pennington et al., 1999). 
6.2 Psychological factors 
A common sensation between the patients with left ventricle assist devices is that of being 
machine-dependent. It is important to indicate a definitive cardiac assist device in very 
strongly motivated patients which may need to be prepared from a psychological point of 
view. A positive psychological feature is the fact that left ventricle assist device insertion 
does not require removal of the natural heart, which might be able to temporarily support 
the circulation, or recover sufficiently to allow for device removal.  
Quality of life may be reasonably satisfactory. Despite externalized battery sources, these 
patients are capable of recovering their daily activities, even returning to work. Although 
patients are capable of concealing external batteries so that it is not so obvious that they are 
supported mechanically, they cannot forget that they are dependent on the device. This 
factor may be resolved with new more modern devices that can be completely implanted 
inside the pericardium or the peritoneum. Presuming the availability of a safe and effective, 
totally implantable, electrically driven, left ventricle assist devices prompts a comparison 
with the current strategy of cardiac transplantation as a universal therapy for patients with 
severe heart failure. 
6.3 Economical factors 
It is very important to be aware of the cost of the implantation of definitive mechanical 
devices. Since there are limited resources availables, it is necessary to demonstrate that they 
are economically feasible. The average total cost to insert a left ventricle assist device in the 
REMATCH patient population was $210,187 which includes a $60,000 charge for the device. 
When implantation hospitalization costs are compared between hospital survivors and 
nonsurvivors, the mean costs increase from $159,271 ± 106,423 to $315,015 ± 278,713.  
Sepsis, pump housing infection, and perioperative bleeding are the major drivers of 
implantation cost, established by regression modeling. In the patients who survived the 
procedure, bypass time, perioperative bleeding, and late bleeding were the drivers of cost. 
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The average annual readmission cost per patient for the overall cohort was $105,326, the cost 
of which was considerably influenced by device reliability (Oz et al, 2003). 
In a recent study published by the Institute of Medicine, cost effectiveness was measured by 
the relationship of costs to quality-adjusted life years (QALYs). It was estimated that the cost 
per quality-adjusted life years in dollars for hemodialysis was $50,000, for two-vessel 
coronary artery bypass grafting, $34,000, and for a total artificial heart for 2 years, 
approximately $105,000.  
The cost calculation of quality-adjusted life years for left ventricle assist devices was not 
calculated, but it was estimated that it would be significantly less than that for a total 
artificial heart. 
If the devices can be relatively problem free and not require multiple readmissions for 
replacement of parts or devices, employers may be receptive to these patients returning to 
work. It is not known whether the relatively low reemployment percentage for cardiac 
transplant patients is related to their need to continue to take expensive medications or 
other medical problems.  
It is possible that within four years, one could return to society with an income greater in 
value than the investment if the individual earns an annual salary of $40,000 per year. 
However, by Poirier’s estimation, circulatory support systems represented a potential to 
increase our gross national product, leading to a higher standard of living. 
The current generation of pumps continue to undergo incremental improvement. These 
devices exhibit smaller and more flexible drivelines or use a totally implantable design that 
eliminates a major gateway for infection. They are being introduced in clinical trials that may 
more fundamentally address the device´s shortcomings observed in the REMATCH study. 
7. Short, long and intermediate ventricle assists devices 
We can divide the ventricle assist devices according to its capacity to be used as support 
during a short, long, or intermediate time, depending on the requirements of patients. The 
following tables describe the indications and the more notable characteristics of the different 
kinds of ventricular assist devices. 
7.1 Intermediate ventricle assist devices 
 
 
Fig. 3. ABIOMED BVS 5000 blood pump. 
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Intermediate 
term devices 
Indications Versions Use Advantages 
Thoratec VAD 
Thoratec 
Paracorporeal 
ventricular Assist 
Device (PVAD) 
Thoratec 
Implantable 
Ventricular Assist 
Device (IVAD) 
The device uses suction 
drainage with pulsatile flow. 
Each ventricle costs 
approximately $50,000 but can 
be maintained with minimal 
personnel 
PVAD has supported patients 
for up to 3.3 years 
Abiomed AB 
5000 
Bridge to 
transplantation 
 
Bridge to 
recovery 
 
RVAD
LVAD
BiVAD 
 
It is compatible with the 
cannulae for the Abiomed BVS 
5000 support system 
Table 3. Intermediate ventricle assist devices: Indications and characteristics. Intermediate 
term devices can be thought of as the true “bridges” to transplantation. They are intended to 
be removed during transplantation and are not designed for constant, permanent support. 
7.2 Short ventricle assists devices 
 
Short term 
VAD 
Specific indications Common indications Use Insertion Limitation 
Centrifugal 
pumps:  
 Bio-Medicus 
 Sarns 
Patients who cannot 
be weaned from 
cardiopulmonary 
bypass.  
Patients who are 
awaiting cardiac 
transplantation. 
RVAD 
LVAD
BiVAD
Sternotomy 
Percutaneously 
(in the 
catheterization 
laboratory) 
Non-pulsatil flow  
The devices are 
traumatic to blood, 
causing hemolysis. 
Patients are unable 
to ambulate or 
exercise with the 
device in place. 
Extracorporeal 
pump:  
 Abiomed 
biventricular 
system (BVS 
5000) 
 AB5000 
It allows recovery of 
end organs and is 
approved for 
postcardiotomy use.
Patients with 
potentially reversible 
heart failure. 
Donor heart 
dysfunction following 
transplantation. 
RVAD 
LVAD
BiVAD
Sternotomy 
The devices are 
more expensive 
than centrifugal 
pumps, but can be 
maintained with 
minimal 
personnel. 
Axial flow 
pumps: 
Impella 
microaxial 
flow device 
Postcardiotomy failure  
Sternotomy 
Percutaneously
Nonpulsatile flow. 
Moderate degree 
of hemolysis and 
thrombocytopenia. 
Percutaneous 
left atrial-to-
femoral-
arterial VAD: 
Tandem 
Heart™ 
Stabilization until 
recovery of 
jeopardized 
myocardium. 
Bridge to definite 
surgical treatment. 
VAD/cardiac 
transplant backup in 
patients undergoing 
high risk surgical 
procedures 
Patients with 
unanticipated post-
operative cardiac 
dysfunction who 
required mechanical 
support with VAD 
support of the right 
ventricles or less 
commonly both 
ventricles.  
Post-operative 
cardiogenic shock. 
 Percutaneously
Complications 
such as severe 
bleeding and acute 
limb ischemia are 
more common 
Table 4. Intermediate ventricle assist devices: Indications and characteristics. 
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7.3 Long ventricle assists devices 
 
 
 
Long term 
devices 
Indications Versions Use Advantages Disadvantages 
Novacor 
device 
Replacement 
therapy for 
patients with 
heart failure 
 LVAD  
Requires 
normal native 
aortic valve 
HeartMate 
I 
(pulsatil 
flow) 
HeartMate I is 
a paracorporeal 
device that 
comes in two 
versions: 
implantable 
pneumatic (IP) 
and vented-
electric (XVE) 
versions 
XVE 
only in a 
LVAD 
Anticoagulation with warfarin 
not required. Low 
thromboembolic rate. 
Outpatient support appears to be 
cost-effective 
Improvement in renal function 
and reduction in pulmonary 
hypertension prior to 
transplantation. 
Improvement in hemodynamic 
measurements at rest and during 
exercise and exercise capacity 
Expensive 
device 
HeartMate 
II 
Bridge to 
transplantation.
 
Destination 
therapy. 
Smaller devices 
and greater 
durability 
 
Improvements in NYHA 
functional class, six minute walk, 
and quality of life 
 
Axial-flow 
impeller 
pumps 
 
Bridge to 
myocyte 
recovery. 
Transplantation
 
Long-term 
support 
Jarvik 2000 
pump 
 
DeBakey pump
RVAD 
Small size 
Low noise 
Absence of a compliance 
chamber. 
The device is practically 
encapsulated by the native 
myocardium, reducing the risk of 
infection around the device. 
Quality of life improved 
significantly 
 
Centrifugal 
continuous 
flow 
pumps 
Undergoing a 
clinical trial as a 
bridge to 
transplantation 
in the US. 
Ventrocor 
VentrAssist 
LVAD. 
Heartware 
HVAD. 
Terrumo 
Duraheart. 
 
 
Energetically more efficient 
Lower tolerances so 
manufacturing is easier and they 
are less prone to thrombosis 
They are potential very durable 
(>10 year life-span) 
Fits in the pericardial space. 
 
 
 
 
Table 5. Long ventricle assist devices: Indications and characteristics. 
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8. Biventricular assist device: why and when should it be implanted? 
It is well described in the literature that between 15-25% of patients with a left ventricle 
assist device will develop a right heart failure, even in those patients with a good 
preoperative right cardiac function. Severe right ventricle failure, requiring insertion of a 
right ventricles assist device, has been proved to negatively affect a successful bridge to 
transplant, increase device-related morbidity, prolong hospital length of stay, and increase 
total hospital cost (Slater JP et al, 1996; Karavan et al, 2002). This can be explained with the 
following: 
1. Pre-existing right ventricle dysfunction. This dysfunction may be latent secondary to 
the augmented preload presented to the right side following left mechanical device 
implantation. 
2. Interventricular septal shifting movement. The mechanical unloading of the left 
ventricle may displace the interventricular septum which may contribute to impaired 
right-sided function. 
3. Other perioperative conditions as ischemia, myocardial stunning, embolism or 
arrythmias. 
It is essential to anticipate which patients will develop right side heart failure, however, 
this may be a difficult task. Several papers have reported preoperative risk factors for 
development of right ventricle failure in patients with implantable left ventricle assist 
devices. A study from Ochiai and colleagues (Ochiai et al, 2002) reported in a large 
number of patients that preoperative circulatory support, female gender, and non-
ischemic etiology of heart failure were significant predictors of right ventricle failure. 
Other risk factors that have been related with the need of right circulatory support are low 
pulmonary artery pressure, low right ventricle stroke work index, preoperative 
ventilation and higher left ventricle assist device scores (Fukamachi et al, 1999, Morgan et 
al, 2004). 
Apart from the difficult task of anticipating which patient will require a right ventricle assist 
device, another important problem is the difficulty associated with anticipating when it is 
the right moment to implant a right ventricle device. It is important to note that while 
optimal timing of right ventricle assist device insertion for severe right ventricle failure after 
left ventricle assist device implantation has yet to be clearly defined, a low threshold for 
early right ventricle assist device insertion may be preferable to subsequent development of 
multisystem organ failure that could potentially develop with a more conservative 
approach.  
Some studies describe that patients with an implantable left ventricle assist device and with 
a prompt right ventricle assist device insertion (within 24 hours) have a better outcome than 
patients in which the right mechanical device was inserted after the first 24 hours (Morgan 
et al, 2004). In general, it is believed that right ventricle assist device insertion should be 
performed early after the development of severe right ventricle failure after left ventricle 
assist device implantation, and that right ventricle assist device support should be 
continued for an adequate duration to allow for right ventricle recovery or until 
transplantation. It is essential that while on RVAD support, opportunities to maximally 
improve the patient’s hemodynamic status and fluid balance, such as the use of continuous 
veno-venous hemofiltration and dialysis, should be pursued.  
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Fig. 4. Biventricular assist device. Cannula implantation. 
9. Conclusions 
Heart transplantation is the gold standard therapy for end stage heart failure disease. 
However, there is a lack of donors and some patients have some kind of contraindications.  
Ventricle assist devices can be used in different clinical situations. The most common 
indication nowadays is bridge to transplantation. As more experience and more modern 
devices are available, better the outcomes. Patients being transplanted with a mechanical 
device can have as good results as patients without a ventricle device.  
In some cases an external cardiac support is required while the heart recovers from an acute 
event. Ventricle assist devices can also be used as a bridge to recovery with excellent results 
using a short term ventricle device. In patients awaiting a transplantation or with a 
contraindication for transplantation a long term cardiac device or the total artificial heart are 
very good options in which a high quality of life can be expected. 
It is important not to delay ventricle device implantation till there is a severe multi-organ 
dysfunction. Patients need to be in the best clinical status when receiving a mechanical 
cardiac support. Biventricular assist devices should be kept in mind as right ventricle failure 
can happen after a left ventricle device implantation.  
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